


PICO ELEMENTS



Each <u>PICO statement</u> requires you to express your agreement with it based on a Likert scale (0-9): 0-3 = disagreement, 4-6 = uncertainty, 7-9 agreement.

The wording of the PICO questions during the 2 rounds of the this streamlined Delphi Technique was not changed substantially.



1. POPULATIONS

- a. **MILDLY-ILL COVID-19 PATIENTS*** presenting to Emergency Department with fever, myalgia, cough, sore throat or other mild symptoms, including exertional dyspnea but not clinically evident acute respiratory failure/hypoxemia, shock, or any other life-threatening or potentially life-threatening condition)
- b. **COVID-19* PATIENTS* with RESPIRATORY FAILURE** including both "Silent Hypoxia" & clinically-overt respiratory failure, either at presentation or along disease course
- c. COVID-19* PATIENTS *with SEVERE EXTRA-PULMONARY SIGNS & SYMPTOMS - such as shock, altered level of consciousness, stroke, suspected acute thromboembolic disease, acute kidney failure, acute peripheral ischemic disease, either at presentation or along disease course

* **COVID-19 patients** refers to patients to be screened for SARS-CoV2 infection at first encounter, or already diagnosed with SARS-CoV2 infection . This is where the PICO Outcomes choices apply: e.g. with the Outcome "More effective diagnosis" and "More effective triage/Disposition" (Outcomes a, b) "COVID-19 PATIENTS" refers to patient at first encounter. However, "More effective monitoring" and all the others Outcomes (Outcomes c-i.), may apply either to first-encounter/unknown SARS-CoV2 infection, or already microbiologically demonstrated SARS-CoV2 infection).

2. INTERVENTIONS

- a. **LUS ALONE** Clinically-integrated lung ultrasound and no other PoCUS applications
- b. **MULTI-ORGAN PoCUS** Clinically-integrated multi-modal, multi-system point-of-care ultrasound, including:
 - Lung Ultrasound
 - Focused Cardiac Ultrasound (+/- hemodynamic measurements)
 - Abdominal scanning of great vessels and kidneys, bladder, gallbladder, liver (potentially including Doppler sampling of kidney artery/vein, Hepatic veins and Portal vein for diagnosis of systemic venous congestion), FAST exam
 - Extremity Duplex compression evaluation for DVT



3. COMPARATORS

- a. **NO LUNG IMAGING** Standard/Institutional diagnostic/monitoring clinical workup without the use of any imaging modalities
- b. **CXR** Standard/Institutional diagnostic/monitoring clinical workup including Chest X-Ray
- c. **CT LUNG -** Standard/Institutional diagnostic/monitoring clinical workup including Chest CT-Scan, plus angio-CT scan if indicated (thoracic great vessels, PE)

4. OUTCOMES

a. MORE EFFECTIVE DIAGNOSIS OF SARS-COV2 INFECTION

• Higher sensitivity, specificity, & accuracy in diagnosing SARS-CoV2 infection

b. MORE EFFECTIVE TRIAGE/DISPOSITION - May include:

- Higher accuracy at assessment of potential SARS-CoV2 disease
- Higher accuracy in severity assessment of COVID-19 patients
- Potentially resulting in more rapid provision and more appropriate <u>level of care</u> and <u>cohorting of patients</u>

c. MORE ACCURATE PULMONARY DIAGNOSIS - May include:

- Better assessment of pulmonary manifestations and progression of disease
- Better assessment of pulmonary conditions other than COVID-19 pneumonia
- Better assessment of superimposed lung conditions

d. MORE ACCURATE CVS DIAGNOSIS - May include:

- Better assessment of cardiovascular manifestations (shock, cardiac arrest, stroke, peripheral ischemia of the limbs or splanchnic circulation) and progression of disease
- Better assessment of cardiac complications

e. MORE ACCURATE VTE DIAGNOSIS

Better assessment of venous thromboembolic manifestations (PE, DVT) & progression of disease



f. MORE EFFECTIVE USE OF MECHANICAL VENTILATION - May include:

- Better assessment of need for MV (non-invasive/invasive)
- More efficient use of MV (help in choice of ventilator modality/settings)
- Better choice of inadequacy of mechanical ventilation and need for extracorporeal support
- Potentially resulting in fewer complications of MV

g. MORE APPROPRIATE FLUID MANAGEMENT

 Better assessment of need of, responsiveness and tolerance to intravenous fluids

h. MORE EFFECTIVE MONITORING - May include:

- Better assessment of lung disease course
- Better assessment of lung aeration & recruitment
- Better assessment of hemodynamics
- Better assessment of cardiac disease course
- Better assessment of thromboembolic disease course
- Better assessment of weaning from mechanical ventilation
- Better monitoring of extracorporeal circulation

i. BETTER INFECTION CONTROL – May include:

- Reduced in-hospital viral spread
- Lower rate of infection amongst healthcare workers



DELPHI ROUNDS RESULTS - SYNOPSIS

ROUND 1 - Synopsis

Strength of Consensus							Direction of Agreement			
	N	VERY GOOD CONSENSUS	GOOD CONSENSUS	SOME CONSENSUS	NO CONSENSUS	AGREE	AMBIV	DISAGREE		
Section 1	43	25,6%	49,2%	20,9%	7,0%	86,0%	6,9%	6,9%		
Section 2	50	34,0%	46,0%	20,0%	0,0%	64,0%	10,0%	6,0%		
Section 2	32	31,3%	59,4%	9,4%	0,0%	93,8%	0,0%	6,2%		
Section 4	4	0,0%	100,0%	0,0%	0,0%	50,0%	50,0%	0,0%		
TOTALS	129	30,7%	49,6%	17,3%	2,4%	86,6%	8,7%	4,7%		

ROUND 2 - Synopsis

			Strength of	Consensus		Dir	ection of Agreem	ent
	N	VERY GOOD CONSENSUS	GOOD CONSENSUS	SOME CONSENSUS	NO CONSENSUS	AGREE	AMBIV	DISAGREE
Section 1	43	51,2%	25,6%	18,6%	7,0%	83,7%	9,3%	7,0%
Section 2	50	34,0%	54,0%	8,0%	4,0%	84,0%	12,0%	4,0%
Section 2	32	56,3%	31,3%	12,5%	0,0%	93,8%	6,3%	0,0%
Section 4	4	0,0%	75,0%	25,0%	0,0%	100,0%	0,0%	0,0%
TOTALS	129	44,2%	39,5%	13,2%	3,9%	86,8%	9,3%	3,9%



PoCUS4COVID Domains

DOMAIN	PoCUS APPLICATION
1	DIAGNOSIS OF SARS-COV2 INFECTION
2	TRIAGE/DISPOSITION
3	DIAGNOSIS OF COVID-19 PNEUMONIA
4	CARDIOVASCULAR DIAGNOSIS
5	SCREENING AND DIAGNOSIS OF THROMBOEMBOLIC DISEASE
6	PoCUS AND RESPIRATORY SUPPORT STRATEGIES
7	MANAGEMENT OF FLUID ADMINISTRATION
8	MONITORING OF COVID-19 PATIENTS
9	INFECTION CONTROL, TECHNIQUES, TECHNOLOGY AND PROTOCOLS



RESULTS and SUMMARY RECOMMENDATIONS

DOMAIN 1 - POCUS FOR DIAGNOSIS OF SARS-COV2 INFECTION

1 - SARS DX	TOTAL		MILD	RESP FAIL	XTR-PULM
I - SARS DA	<u>N = 18</u>	<u>%</u>	<u>N = 7</u>	<u>N = 7</u>	<u>N = 4</u>
VG	0	0,0%	0	0	0
G	10	55,6%	3	5	2
S	6	33,3%	3	1	2
NC	2	11,1%	1	1	0
AGREE	10	55,6%	4	4	3
AMBIV	2	11,1%	2	2	1
DISAGREE	5	27,8%	1	1	0

GRAD	Eing	<u>N = 11</u>	IBID	CONS
<u>2A</u>	<u>2B</u>	<u>3</u>		
5	4	2	3	G

DOMAIN 2 - POCUS AS A TOOL FOR TRIAGE/DISPOSITION

2 - TRG/DISP	<u>TOTAL</u>		MILD	RESP FAIL	XTR-PULM
<u>z - 110/DISP</u>	<u>N = 18</u>	<u>%</u>	<u>N = 7</u>	<u>N = 7</u>	<u>N = 4</u>
VG	5	27,8%	2	1	2
G	11	61,1%	4	5	2
S	2	11,1%	1	1	0
NC	0	0,0%	0	0	0
AGREE	16	88,9%	6	6	4
AMBIV	2	11,1%	1	1	0
DISAGREE	0	0,0%	0	0	0

GRAD 2A	Eing	<u>N = 14</u>	CONS G
<u>2A</u>	<u>2B</u>	<u>3</u>	G
1	7	6	

DOMAIN 3 - POCUS AS A TOOL FOR TRIAGE/DISPOSITION

<u>3 - PULM DX</u>	TOTAL		MILD	RESP FAIL	XTR-PULM
<u>3 - FULINI DA</u>	<u>N = 18</u>	<u>%</u>	<u>N = 7</u>	<u>N = 7</u>	<u>N = 4</u>
VG	7	38,9%	4	2	1
G	4	22,2%	0	3	1
S	4	22,2%	1	1	2
NC	3	16,7%	2	1	0
AGREE	13	72,2%	5	5	3
AMBIV	2	11,1%	0	1	1
DISAGREE	3	16,7%	2	1	0

GRAD	Eing	<u>N = 53</u>	CONS G
<u>2A</u>	<u>2B</u>	<u>3</u>	G
5	18	28	



- 1) We suggest using PoCUS, and especially LUS (presence of heterogeneous B-line clusters, pleural line irregularities, subpleural consolidations), and appropriately integrate the information with clinical assessment to diagnose COVID-19 pneumonia (LQE II-B, Very Good Agreement).
- When CT-scan is not accessible or appropriate, we suggest using LUS to aid the diagnosis of COVID-19 pneumonia in suspected cases (LQE II-B, Good Agreement).
- 3) In patients with high pre-test probability for COVID-19 and LUS findings suggestive of pneumonia, a negative nasal/oropharyngeal RT-CR may not be used to exclude COVID-19, and LUS findings, further raising suspicion, should prompt repeat testing with better yield (LQE II-B, Good Agreement).
- 4) We do *not* recommend using PoCUS and LUS alone to rule out SARS-CoV-2 infection in suspected COVID-19 (LQE II-B, Good Agreement).
- 5) After thorough examination of all lung fields and intercostal spaces a bilateral A-pattern suggests absence of pneumonia in suspected or confirmed SARS-CoV-2 infection (LQE III, Good Agreement).
- 6) We suggest multi-organ PoCUS integrated with other clinical information for triaging and risk stratification of suspected COVID-19 at initial presentation (LQE II-B, Good Agreement).



DOMAIN 4 - FoCUS, and Comprehensive Echocardiography for the Cardiovascular Diagnosis in COVID-19 patients

CONS

VG

49

4 - CVS DX	TOTAL		MILD	RESP FAIL	XTR-PULM	(GRAD	Eing	<u>N = 26</u>	
<u>4-073 DA</u>	<u>N = 12</u>	<u>%</u>	<u>N = 4</u>	<u>N = 4</u>	<u>N = 4</u>		<u>2A</u>	<u>2B</u>	<u>3</u>	
VG	10	83,3%	4	3	3		1	10	15	
G	2	16,7%	0	1	1					
S	0	0,0%	0	0	0					
NC	0	0,0%	0	0	0					
AGREE	12	100,0%	4	4	4					
AMBIV	0	0,0%	0	0	0					
DISAGREE	0	0,0%	0	0	0					

- We suggest FoCUS and/or echocardiography assessment in moderate-severe COVID-19 as it may change clinical management or provide information that could be lifesaving (LQE II-B, Very Good Agreement).
- 8) We suggest FoCUS and/or echocardiography for assessment of hemodynamic instability in moderatesevere COVID-19 (LQE II-B, Very Good Agreement).
- 9) We recommend FoCUS and echocardiography to diagnose RV and LV systolic dysfunction and cardiac tamponade as etiology of hemodynamic instability in COVID-19 (LQE II-B, Very Good Agreement).
- 10) We suggest using FoCUS/echocardiography to guide hemodynamic management in severe COVID-19 (LQE II-B, Very Good Agreement).



DOMAIN 5 - POCUS FOR SCREENING AND DIAGNOSIS OF COVID-19 PATIENTS FOR VENOUS THROMBOEMBOLIC DISEASE (VTE)

5 - VTE DX	TOTAL		MILD	RESP FAIL	XTR-PULM
<u>3-VIEDA</u>	<u>N = 12</u>	<u>%</u>	<u>N = 4</u>	<u>N = 4</u>	<u>N = 4</u>
VG	9	75,0%	3	3	3
G	2	16,7%	1	1	1
S	1	8,3%	0	0	0
NC	0	0,0%	0	0	0
AGREE	12	100,0%	4	4	4
AMBIV	0	0,0%	0	0	0
DISAGREE	0	0,0%	0	0	0

GRAD	GRADEing 2A 2B 10 12			CONS VG		
<u>2A</u>	<u>2B</u>	<u>3</u>	12	VG		
10	12	10				

- 11) Because critically ill COVID-19 patients have high risk for VTE, we suggest regular screening for DVT, including central vessels with catheters, independent of oxygenation and coagulation (LQE II-A, Very Good Agreement).
- 12) In moderate-severe COVID-19 with hemodynamic worsening or sudden instability we suggest FoCUS for prompt investigation of acute cor-pulmonale (LQE II-B, Very Good Agreement).
- 13) In moderate-severe COVID-19 we suggest that echocardiographic indices of worsening RV function and/or increased pulmonary artery pressure may indicate PE (LQE II-A, Very Good Agreement).



DOMAIN 6 - POCUS AND RESPIRATORY SUPPORT STRATEGIES [INCLUDING MECHANICAL VENTILATION] IN PATIENTS WITH COVID-19 PNEUMONIA

ONS G

	TOTAL		MILD	RESP FAIL	XTR-PULM	GRA	DEing	<u>N = 20</u>		CO
<u>6 - RESP SUPP</u>	<u>N = 11</u>	<u>%</u>	<u>N = 0</u>	<u>N = 7</u>	<u>N = 4</u>	<u>2A</u>	<u>2B</u>	<u>3</u>	35	(
VG	4	36,4%	0	2	2	2	11	7	36	
G	7	63,6%	0	5	2				41	
S	0	0,0%	0	0	0					
NC	0	0,0%	0	0	0					
AGREE	10	90,9%	0	6	4					
AMBIV	1	9,1%	0	1	0					
DISAGREE	0	0,0%	0	0	0					

- 14) We suggest multi-organ PoCUS including LUS over no imaging to guide respiratory support in COVID 19 with respiratory failure (i.e. ventilation, prone positioning, PEEP, recruitment maneuvers) (LQE II-A,
 Good Agreement).
- 15) In addition to standard respiratory monitoring, we suggest LUS over CXR and equally to CT, to guide clinical decisions on respiratory support in COVID-19 with respiratory failure (LQE II-B, Good Agreement).
- 16) We suggest multi-organ PoCUS over LUS alone for decisions about respiratory support in COVID-19 with respiratory failure (LQE II-B, Good Agreement).



DOMAIN 7 - POCUS FOR MANAGEMENT OF FLUID ADMINISTRATION IN COVID-19 PATIENTS

7 - FLD MAN	TOTAL		MILD	RESP FAIL	XTR-PULM	GRAD	DEing
<u>7 - FLD IMAN</u>	<u>N = 18</u>	<u>%</u>	<u>N = 7</u>	<u>N = 7</u>	<u>N = 4</u>	<u>2A</u>	<u>2</u> E
VG	11	61,1%	4	3	4	0	7
G	5	27,8%	1	4	0		
S	2	11,1%	2	0	0		
NC	0	0,0%	0	0	0		
AGREE	16	88,9%	6	6	4		
AMBIV	2	11,1%	1	1	0		
DISAGREE	0	0,0%	0	0	0		

GRAD	GRADEing 2A 2B			CONS VG	
<u>2A</u>	<u>2B</u>	<u>3</u>	5	VG	
0	7	2			

- 17) We suggest FoCUS to screen for severe hypovolemia in moderate-severe COVID-19 at presentation, while Doppler-based fluid-responsiveness indices may be used for subsequent management (LQE II-A, Very Good Agreement).
- 18) We suggest that LUS alone is not sufficient as a screening tool for pulmonary congestion in moderatesevere COVID-19 (LQE III, Very Good Agreement).
- 19) We suggest that LUS alone is not sufficient to judge the appropriateness of fluid administration in moderate-severe COVID-19 (LQE II-B, Very Good Agreement).
- 20) In moderate-severe COVID-19 we suggest multi-organ PoCUS to monitor efficacy of fluid removal, by not only LUS findings of reduction of B-pattern areas, but also echocardiographic signs of resolution of volume overload and decreasing LV filling pressures (LQE II-B, Very Good Agreement).



DOMAIN 8 - PoCUS as monitoring tool for Patients with COVID-19

8 - MONITOR	TOTAL		MILD	RESP FAIL	XTR-PULM	GF
	<u>N = 18</u>	<u>%</u>	<u>N = 7</u>	<u>N = 7</u>	<u>N = 4</u>	2
VG	11	61,1%	5	3	3	
G	7	38,9%	2	4	1	
S	0	0,0%	0	0	0	
NC	0	0,0%	0	0	0	
AGREE	18	100,0%	7	7	4	
AMBIV	0	0,0%	0	0	0	
DISAGREE	0	0,0%	0	0	0	

GRAD	Eing	<u>N = 49</u>		CONS VG
<u>2A</u>	<u>2B</u>	3	10	VG
4	29	16	11	
			25	
			49	
			51	
			64	
			66	
			67	

- 21) We suggest serial LUS for respiratory monitoring in moderate-severe COVID-19 (LQE II-B, Very Good Agreement).
- 22) We suggest multi-organ PoCUS integrated with other clinical and biochemical variables, in preference to CXR for investigation of respiratory deterioration in moderate-severe COVID-19. (LQE II-A, Very Good Agreement).
- 23) We suggest multi-organ PoCUS over LUS alone to detect respiratory deterioration and guide treatment in moderate-severe COVID-19. (LQE II-B, Very Good Agreement).
- 24) We suggest a prompt assessment of clinical deterioration with LUS for a timely and accurate bedside diagnosis of pneumothorax in severe COVID-19 (LQE II-B, Very Good Agreement).
- 25) We suggest LUS for early identification of ventilator-associated pneumonia in severe COVID-19 (LQE II-B, Very Good Agreement).
- 26) We suggest multi-organ PoCUS over CXR and CT to assess readiness for weaning, predict success, and diagnose the cause(s) of weaning failure in COVID-19 (LQE II-B, Very Good Agreement).
- 27) We suggest FoCUS, and/or echocardiography for hemodynamic monitoring in moderate-severe COVID-19 (LQE II-A, Very Good Agreement).
- 28) We suggest integrating PoCUS-derived information with data from other devices used for hemodynamic monitoring in severe COVID-19 (LQE II-B, Very Good Agreement).
- 29) We suggest PoCUS assessment for pre-renal causes of AKI, including hemodynamics and venous congestion in COVID-19 (LQE II-B, Very Good Agreement).



DOMAIN 9 - POCUS AND INFECTION CONTROL, POCUS TECHNIQUE, TECHNOLOGY,

PROTOCOLS

<u>9 - INF CON</u>	<u>N = 4</u>	<u>%</u>	
VG	0	0,0%	
G	3	75,0%	
S	1	25,0%	
NC	0	0,0%	
AGREE	4	100,0%	
AMBIV	0	0,0%	
DISAGREE	0	0,0%	

GRADEing			N = 23	CONS		
<u>2</u> A	<u>2B</u>	<u>3</u> 5			G	
4	14	5				

- 30) We suggest using laptop/tablet/pocket-sized devices with adequate imaging capabilities that are easier to protect from viral contamination in COVID-19 (LQE II-B, Good Agreement).
- 31) For diagnostic accuracy, quality control and obtaining second opinions, we suggest performance of standardized PoCUS examinations in COVID-19 (LQE II-B, Good Agreement).
- 32) We recommend reporting PoCUS studies and recording, storage and archiving of diagnostic images and cine-clips (LQE II-B, Good Agreement).
- 33) We suggest using tele-ultrasound for remote guidance and consultations in COVID-19. Simple audiovisual communication devices (e.g. smartphones) can facilitate this **(LQE II-B, Good Agreement)**.
- 34) We suggest POCUS over CXR and CT, where appropriate, to reduce environmental spread of infection and risk of infection to healthcare workers in COVID-19 (LQE II-A, Good Agreement).
- 35) We recommend strict adherence to manufacturers' guidance for cleaning and disinfection of equipment used for COVID-19 (LQE II-A, Good Agreement).
- 36) We suggest brief and targeted ultrasound examinations to minimize cross-infection in COVID-19 (LQE II-B, Good Agreement).